Q-omics provides the consensus-scored ZC3H12D profile across patient tissues and cancer cell-line models. ZC3H12D expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZC3H12D is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZC3H12D RNA expression shows 19,312 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where ZC3H12D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3H12D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3H12D survival associations across molecular data types. ZC3H12D RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3H12D RNA expression–survival associations across cancer types. High ZC3H12D expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, LUAD, READ and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZC3H12D RNA expression.
This table summarizes ZC3H12D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZC3H12D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3H12D shows lower tumor expression in KICH, KIRP and COAD and higher tumor expression in KIRC, HNSC and STAD. The KIRC box plot shows higher ZC3H12D RNA expression in tumor versus normal tissue (log2 FC = +0.738, t-test p < 0.001).
This table shows molecular features associated with ZC3H12D in patient tissues and cancer cell lines. In patient samples, ZC3H12D shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3H12D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
